electroCore Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue rose 28% year-over-year to $9.5 million, driven by VA and Quell growth. Guidance was raised to over 30% annual revenue growth, with improved profitability and a path to positive adjusted EBITDA by Q3 2027. Major sales force expansion and operational changes support future growth.
-
Strong revenue growth and margin expansion are driven by prescription and wellness products, with significant upside in the VA and new commercial channels. Strategic focus includes expanding indications, optimizing sales, and leveraging a robust IP portfolio for future growth.
-
The company has achieved strong revenue growth by focusing on federal markets, especially the VA, and expanding its product suite through strategic acquisitions and innovation. With significant market opportunities ahead, ongoing clinical trials, and a clean capital structure, the business is positioned for further expansion and profitability.
-
The company highlighted strong revenue growth, expanding product lines for chronic pain, and strategic partnerships with the VA and Kaiser Permanente. Key differentiators include proprietary cervical vagus nerve stimulation technology and a focus on operational efficiency and new market opportunities.
-
Record Q1 revenue grew 43% year-over-year to $9.6M with 87% gross margin, driven by VA and consumer channels. Leadership transition completed, guidance for 30% full-year growth reaffirmed, and strong operating leverage demonstrated.
Fiscal Year 2025
-
Record 2025 revenue growth was driven by VA and wellness channels, with strong Truvaga sales and improved gross margin. Leadership transition is underway, and 2026 revenue is expected to grow ~30%, with new product launches and expanded federal and managed care focus.
-
Q3 2025 revenue rose 33% year-over-year to $8.7M, driven by VA channel growth and the Quell Fibromyalgia acquisition. Gross margin improved to 86%, and full-year guidance was raised. Profitability is delayed to fund expansion, with positive adjusted EBITDA expected in H2 2026.
-
Record Q2 revenue of $7.4M (up 20% YoY) driven by VA and wellness growth, with gross margin at 87%. Strategic investments are accelerating, delaying profitability but targeting $11.5–$12M in quarterly revenue for cash flow positivity.
-
Q1 2025 revenue rose 23% year-over-year to $6.7 million, with strong growth in VA and direct-to-consumer channels. Gross margin improved to 85%, and the Neurometrics acquisition expands the product portfolio. Full-year revenue is projected at $30 million, with a path to cash neutrality by late 2025.
-
Revenue growth remains strong with expanding insurance coverage and a diversified product portfolio. New clinical indications, recent acquisitions, and direct-to-consumer initiatives are expected to drive further growth and approach cash flow positivity.
-
Non-invasive neuromodulation products for headache, wellness, and military use drove $25M in 2024 revenue, with strong gross margins and expanding coverage. New acquisitions and clinical trials target PTSD, fibromyalgia, and substance abuse, supporting growth into 2026.
Fiscal Year 2024
-
Record 2024 revenue rose 57% to $25.2M, driven by VA and Truvaga sales, with gross margin at 85% and net loss narrowing by 37%. Key growth initiatives include the NeuroMetrix acquisition, new product launches, and expanded DTC channels.
-
Q3 2024 revenue rose 45% year-over-year to $6.6M, with gross margin steady at 84% and net loss narrowing by 38%. VA channel and Truvaga sales drove growth, while TAC-STIM revenue was variable but supported by a large Q4 military order. Cash use declined, and positive cash flow is expected next year.
-
Strong revenue growth, high gross margins, and a diversified product portfolio drive expansion in prescription, wellness, and military markets. Pipeline advances in PTSD and substance abuse, with robust patent protection and plans for broader insurance coverage in 2025-2026.
-
Q2 2024 saw record revenue of $6.1M (up 73% YoY), 86% gross margin, and a 46% reduction in net loss. VA channel sales surged 120%, Truvaga and TAC-STIM product lines expanded, and $9M was raised, mostly from insiders. Positive cash flow is targeted for early next year.